Christina Ruhlmann
10PUBLICATIONS
33CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (10)
Sort by Publication Date:
|Jan 10, 2026
The Prognostic Value of Biomarkers Identified by [<sup>18</sup>F]FDG-PET/CT in Patients with High-Risk Melanoma Treated with Adjuvant Immunotherapy.Anne-Line Mayland Madsen, Oke Gerke, Christina H Ruhlmann
|Oct 19, 2025
Dabrafenib plus trametinib vs encorafenib plus binimetinib in BRAF-mutant metastatic melanoma: a real-world propensity score-matched survival analysis.Yago Garitaonaindia, Shawez Khan, Rasmus Friis
|Feb 26, 2025
Patient and Caregiver Education to Support Self-Efficacy and Self-Management During Immunotherapy-An Integrative Review.Camilla S Rothausen, Karin B Dieperink, Christina H Ruhlmann
|Jul 27, 2024
Efficacy of Ipilimumab and Nivolumab in Patients with Melanoma and Brain Metastases-A Danish Real-World Cohort.Karoline Dreyer Kattenhøj, Christine Louise Møberg, Louise Mahncke Guldbrandt
|Apr 10, 2024
Frequency and characteristics of immune-related thyroid adverse events in patients with resected stage III/IV melanoma treated with adjuvant PD-1 inhibitors: a national cohort study.Stine K Christensen, Mette L Winther, Ida J Laursen
|Dec 19, 2023
2023 updated MASCC/ESMO consensus recommendations: controlling nausea and vomiting with chemotherapy of low or minimal emetic potential.Ian Olver, Rebecca Clark-Snow, Christina H Ruhlmann
Pageof 2
Frequent Collaborators
4 joint publications
Eva Ellebaek
3 joint publications
Inge Marie Svane
3 joint publications
Marco Donia
3 joint publications
Henrik Schmidt
2 joint publications
Sebastian Werngreen Nielsen
2 joint publications
Lise Eckhoff
2 joint publications
Jørn Herrstedt
2 joint publications
Susanne Oksbjerg Dalton
2 joint publications
Rasmus Friis
1 joint publications
Dorthe Brønnum
